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Background: Chronic kidney disease is common in HIV positive patients and renal tubular dysfunction has
been reported in those receiving combination antiretroviral therapy (cART). Tenofovir (TFV) in particular has
been linked to severe renal tubular disease as well as proximal tubular dysfunction. Markedly elevated urinary
concentrations of retinal-binding protein (RBP) have been reported in patients with severe renal tubular disease,
and low-molecular-weight proteins (LMWP) such as RBP may be useful in clinical practice to assess renal tubular
function in patients receiving TFV. We analysed 3 LMWP as well as protein and albumin in the urine of a
sample of HIV positive patients.
Methods: In a cross-sectional fashion, total protein, albumin, RBP, cystatin C, and neutrophil gelatinase-associated
lipocalin (NGAL) were quantified in random urine samples of 317 HIV positive outpatients and expressed as
the ratio-to-creatinine (RBPCR, CCR and NGALCR). Exposure to cART was categorised as none, cART without TFV,
and cART containing TFV and a non-nucleoside reverse-transcriptase-inhibitor (TFV/NNRTI) or TFV and a
protease-inhibitor (TFV/PI).
Results: Proteinuria was present in 10.4 % and microalbuminuria in 16.7 % of patients. Albumin accounted for
approximately 10 % of total urinary protein. RBPCR was within the reference range in 95 % of patients while
NGALCR was elevated in 67 % of patients. No overall differences in urine protein, albumin, and LMWP levels were
observed among patients stratified by cART exposure, although a greater proportion of patients exposed to TFV/PI
had RBPCR >38.8 μg/mmol (343 μg/g) (p = 0.003). In multivariate analyses, black ethnicity (OR 0.43, 95 % CI 0.24,
0.77) and eGFR <75 mL/min/1.73 m2 (OR 3.54, 95 % CI 1.61, 7.80) were independently associated with upper
quartile (UQ) RBPCR. RBPCR correlated well to CCR (r2 = 0.71), but not to NGALCR, PCR or ACR.
Conclusions: In HIV positive patients, proteinuria was predominantly of tubular origin and microalbuminuria was
common. RBPCR in patients without overt renal tubular disease was generally within the reference range, including
those receiving TFV. RBP therefore appears a promising biomarker for monitoring renal tubular function in patients
receiving TFV and for distinguishing patients with normal tubular function or mild tubular dysfunction from those
with severe renal tubular disease or Fanconi syndrome.
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Chronic kidney disease (CKD) is present in approxi-
mately 15 % of HIV positive patients [1]. Uncontrolled
HIV replication has been associated with the develop-
ment of HIV-associated nephropathy (HIVAN) [2-4],
CKD progression and loss of kidney function [3,5,6],
while the use of combination antiretroviral therapy
(cART) may improve renal function [7-9], reduce the in-
cidence of acute renal failure [10], and delay progression
to end-stage kidney disease [3,11,12]. However, specific
antiretrovirals including tenofovir (TFV), indinavir and
atazanavir have been associated with the development
or progression of CKD [13-15], and current guidelines
recommend screening for CKD at baseline in all HIV
infected patients, and regularly thereafter for all or those
at increased risk of CKD using estimated glomerular
filtration rate (eGFR) and urinalysis [16-18].
Renal tubular disease and Fanconi syndrome have
emerged as clinically significant complications of cART,
and are most commonly observed with TFV [19]. The
majority of reported cases of Fanconi syndrome have
arisen in patients aged >40 years who received TFV
together with didanosine or ritonavir-boosted protease
inhibitors (TFV/PI) [20-23]. Milder forms of tubular
dysfunction (defined by variable criteria) have been
reported in 12-81 % of HIV positive patients on cART
[24-27]. In these studies, tubular dysfunction was asso-
ciated with older age [24,26-28], lower weight or BMI
[26,27], diabetes mellitus [29], use of TFV [24,26,29-31]
or TFV/PI [26], and with genetic polymorphisms in
subjects exposed to TFV [28,32].
In patients with tubular dysfunction or Fanconi
syndrome, an impaired ability of the proximal renal tu-
bule to reabsorb phosphate, glucose, urate, amino acids
and low molecular weight proteins (LMWP) from the
glomerular ultrafiltrate results in increased urinary loss
of these molecules. Retinol-binding protein (RBP) and
cystatin C are examples of LMWP that are found in
increased amounts in urine from patients with Fanconi
syndrome [21,33]. It has been proposed that these
biomarkers may be useful in the diagnosis of Fanconi
syndrome and to monitor and detect tubular dysfunction
in patients receiving TFV [34]. Neutrophil gelatinase-
associated lipocalin (NGAL) is another LMWP, which is
highly induced during inflammation and found to be a
sensitive, early marker of acute kidney injury [35]. How-
ever, concentrations of these LMWP in urine of HIV
positive patients and their associations with demographic
and clinical parameters have not been well defined.
The objective of the present study was to examine the
concentrations of different LMWP (RBP, cystatin C and
NGAL) in relation to total protein and albumin excre-
tion in urine of HIV positive patients, and to investigate
possible factors associated with the highest quartile ofurinary concentrations of these LMWP, with particular
emphasis on the type of cART used.
Methods
Study population
We conducted a cross sectional study of consecutive
HIV positive outpatients who attended King’s College
Hospital, London, UK between 8/2006 and 8/2007.
Patients were included if they agreed to participate in
the study irrespective of the presence of kidney disease
or risk factors for kidney disease. The study was
approved by the local NHS research ethics committee
(LREC) and all subjects provided informed consent.
For each subject, demographic, clinical and laboratory
data were obtained from the clinic database and elec-
tronic hospital records. In addition, a detailed medical
history was obtained, and height, weight, and waist
circumference were measured. Three clinic blood pres-
sure (BP) measurements were recorded of which the
average of the second and third reading was used for the
analysis. Blood samples were taken for routine biochem-
istry including renal, liver, bone, and lipid profiles, full
blood count, CD4 T cell count and HIV RNA level. In
addition, spot urine samples were obtained for measure-
ment of creatinine, protein and albumin; an aliquot of
urine was stored at −70°C for measurement of RBP,
cystatin C and NGAL.
Definitions
A diagnosis of hypertension was based on levels of sys-
tolic BP ≥140 or diastolic BP ≥90 mmHg or current
treatment of hypertension with antihypertensive drugs
[36]. Diabetes was defined by a prior diagnosis by a
health care professional, use of anti-hyperglycaemic
medication, or the need to follow a diabetic diet. eGFR
was calculated with the 4-variable Modification of Diet
in Renal Disease (MDRD) equation, incorporating age,
gender and ethnicity [17]. Proteinuria was defined as
urine protein-to-creatinine ratio (PCR) >20 mg/mmol
(approximately >200 mg/g), macroalbuminuria as albumin-
to-creatinine ratio (ACR) >30 mg/mmol (approximately
>300 mg/g), and microalbuminuria as ACR 3–30 mg/
mmol (approximately 30–300 mg/g), respectively. Expos-
ure to cART was categorised as none, cART not contain-
ing TFV, cART containing TFV and a non-nucleoside
reverse transcriptase inhibitor but no PI (TFV/NNRTI),
or cART containing TFV/PI.
Analytical methods
Urine albumin was measured using a polyethylene
enhanced immunoturbidimetric assay, urine protein
using the pyrogallol red method and creatinine with
the kinetic Jaffe method on the ADVIA 2400 analyser
(Siemens Healthcare Diagnostics Ltd, Camberley, UK).
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immunosorbent assay (ELISA; Immundiagnostik, Ben-
sheim, Germany; reference range 0.01-0.54 mg/L), cysta-
tin C by latex-enhanced immunoturbidimetric assay
(Siemens Healthcare Diagnostics Ltd, Camberley, UK;
no reference range supplied), and NGAL by ELISA (Bio-
Porto Diagnostics, Gentofte, Denmark, reference range
0.7-9.8 μg/L), all with intra- and inter-assay variability of
<5% and <10% respectively. For reasons of comparison,
the urinary concentration of all LMWP was expressed
relative to the urinary creatinine concentration (in
mmol/L or g/L) as RBP/creatinine ratio (RBPCR), cysta-
tin C/creatinine ratio (CCR), and NGAL/creatinine ratio
(NGALCR).
Statistical analysis
Statistical analyses were performed using STATA version
11 (StataCorp, College Station, TX, USA). Categorical
variables are presented as absolute frequencies and the
relevant percentages. Depending on the distribution,
continuous variables are presented as means ± standard
deviation (mean ± SD) or as medians with inter-quartile
ranges. In view of their skewed distribution, PCR, ACR
and LMWP measurements were also compared follow-
ing log transformation. Clinical and laboratory para-
meters were described, and compared for patients
stratified by cART regimen using chi-squared or Fisher’s
exact test (categorical variables), Analysis of Variance or
Kruskal-Wallis test (continuous variables). Correlations
between the different LMWP and PCR were assessed
using Pearson’s correlation coefficient, following log
transformation of RBPCR and PCR, and square root
transformation of CCR and NGALCR, in view of their
skewed distribution.
The assays to quantify LMWP in urine are poorly
standardised and the reference ranges for persons with-
out kidney disease have not been widely validated.
Hence, factors associated with the upper quartile (UQ)
of RBPCR, CCR and NGALCR measurements were
examined in logistic regression analyses. Variables were
tested for interaction and included in the multivariate
models if p was <0.05 in univariate analysis.
Results
A total of 317 patients were studied. Demographic and
clinical characteristics of the study cohort are depicted
in Table 1. The mean age was 41years, 70% of patients
were men, 60% of black ethnicity, and HIV infection was
acquired through sex between men and IV drug use in
40% and 2% respectively. The median nadir and current
CD4 count of the patients were 171 and 389 cells/mm3
respectively, 82% were taking cART at the time of sam-
pling, and 65% had plasma HIV RNA levels <50 copies/
mL. The median eGFR was 89 mL/min/1.73 m2; of note,only 4% and 2% of patients respectively had eGFR <60
and <50 mL/min/1.73 m2. Hypertension and diabetes
mellitus was present in 15% and 4% of patients respect-
ively, and 5% and 6% were co-infected with hepatitis B
or C (Table 1).
As shown in Table 1, there were no significant differ-
ences between the groups of patients in terms of age,
gender and ethnicity, with the exception of fewer men
who received cART without tenofovir. Progressive
increases from naive patients to patients receiving TFV/
PI were noted in time since HIV diagnosis and time
since starting cART. Patients receiving cART had lower
nadir CD4 cell counts and more often experienced an
AIDS-defining illness.
Proteinuria, macroalbuminuria and microalbuminuria
were present in 10.4%, 0.6% and 16.7% of patients re-
spectively. There were no significant differences in the
levels of urine protein and albumin excretion between
the groups studied, although a trend towards lower
values among patients not receiving cART was observed
(Table 2). In patients with proteinuria, the median ratio
of ACR/PCR was 9.9 (6.3, 27.0) percent, suggesting that
albumin was a relatively small fraction of total urinary
protein. Of the LMWP, good correlation between
RBPCR and CCR was observed (r2 = 0.71 [95% CI 0.64,
0.77]) (Figure 1A). By contrast, NGALCR correlated
poorly with RBPCR (r2 = 0.12 [0.008, 0.22]) (Figure 1B)
or CCR (r2 = 0.03 [−0.09, 0.16]), and all LMWP corre-
lated poorly with either PCR or ACR (r2 <0.4)
(Figure 1C-D).
We observed no significant differences in LMWP ex-
cretion between the groups compared. However, RBPCR
values >38.8 μg/mmol (>343.5 μg/g), a threshold previ-
ously associated with clinically significant renal tubular
disease [21], was present in 5-8% of patients not receiv-
ing TFV/PI compared to 20 % of those receiving TFV/PI
(p = 0.003), as shown in Figure 2. When applying the
RBP and NGAL reference ranges provided by the manu-
facturers to our patients (using the median weight of
74.2 kg and assuming urine output of 0.5 mL/kg/hr), 17
(5.4%, including 4 patients exposed to TFV/NNRTI and
3 to TFV/PI) and 212 (66.9%) of our patients had
RBPCR and NGALCR measurements above the upper
limit (>48.1 μg/mmol [>425.8 μg/g] and >873 ng/mmol
[>7724 ng/g], respectively).
In univariate analysis, older age, eGFR <90 mL/min/
1.73 m2, longer time since HIV diagnosis, and treatment
with TFV/PI signified a higher odds ratio of UQ RBPCR,
whereas black ethnicity was associated with reduced
odds of UQ RBPCR (Table 3). After adjustment, ethni-
city and eGFR <75 mL/min/1.73 m2 were independently
associated with UQ RBPCR, while a trend towards
higher risk with TFV/PI was observed (p = 0.10). Longer
duration of TFV exposure was not associated with
ble 1 Demographic and clinical characteristics of the total study population and the four study groups
All patients No cART cART/no TFV cART/TFV p-valu FV/NNRTI TFV/PI p-value
mber of patients N (% of total) 317 (100) 57 (18) 143 (45) 117 (37) 2 (23) 45 (14)
e (years) Mean (SD) (range) 41.0 (8.9) (24.4, 64.3) 38.0 (8.5) (21.2, 60.2) 40.9 (8.9) (25.8, 63.3) 42.3 (8.8) (25.7, 70.1) 0.83 2.3 (9.3) (21.7, 65.8) 42.6 (7.3) (27.5, 63.3) 0.30
ale gender N (%) 222 (70) 43 (75) 89 (62) 90 (77) 0.02 4 (75) 36 (80) 0.53
ack Ethnicity N (%) 189 (60) 31 (54) 95 (66) 63 (54) 0.08 5 (49) 28 (62) 0.15
me since HIV diagnosis (years) Median (IQR) 4.9 (2.1, 8.7) 2.0 (0.5, 4.2) 5.1 (2.2, 8.2) 5.8 (3.1, 4.7) 0.0001 .1 (2.5, 8.2) 7.8 (4.1, 11.4) 0.003
me since start cART (years) Median (IQR) 4.6 (2.6, 7.6) 3.2 (2.6, 5.9) 4.3 (2.6, 6.8) 4.8 (2.6, 8.1) 0.51 .5 (2.5, 7.3) 6.0 (3.1, 9.2) 0.009
DS (CDC status C) (N, %) 77 (17) 1 (2) 27 (19) 33 (28) <0.000 7 (24) 16 (35) 0.16
dir CD4 count (cells/mm3) Median (IQR) 171 (71, 262) 290 (230, 416) 161 (69, 250) 146 (64, 210) 0.0001 58 (82, 224) 94 (25, 222) 0.07
rrent CD4 count (cells/mm3) Median (IQR) 389 (270, 532) 437 (329, 560) 363 (269, 534) 385 (259, 517) 0.13 85 (245, 512) 376 (249, 566) 0.62
rrent HIV RNA (log10) Mean (SD) 2.4 (1.3) 3.9 (1.1) 2.2 (1.1) 2.0 (1.0) 0.0001 .1 (1.1) 2.1 (1.0) 0.04
V RNA <50 c/mL N (%) 204 (65) 4 (9) 110 (77) 90 (77) <0.000 0 (83) 30 (67) <0.0001
patitis B surface Ag (positive) N (%) 15 (5) 3 (5) 4 (3) 8 (7) 0.31 (6) 4 (9) 0.49
patitis C Antibody (positive) N (%) 20 (6) 3 (5) 3 (2) 14 (12) 0.005 0 (14) 4 (9) 0.42
FR (mL/min/1.73 m2) Median (IQR) 89 (78, 99) 91 (81, 99) 89 (80, 100) 85 (77, 97) 0.08 6 (76, 97) 82 (76, 96) 0.84
iabetes N (%) 11 (4) 0 (0) 7 (6) 4 (4) 0.27 (3) 2 (5) 0.62
pertension N (%) 39 (15) 5 (12) 20 (16) 14 (13) 0.75 1 (17) 3 (8) 0.16
eight (Kg) Median (IQR) 74.2 (66.0, 82.0) 76.0 (68.9, 85.0) 74.3 (65.6, 82.0) 73.5 (66.0, 82.9) 0.39 3.6 (66.4, 81.0) 71.1 (65.6, 84.9) 0.73
I Median (IQR) 24.6 (22.9, 28.1) 25.6 (22.5, 31.4) 25.5 (22.4, 29.6) 23.9 (21.9, 27.1) 0.06 4.1 (22.1, 26.8) 23.5 (21.4, 27.7) 0.73
value for comparison between study groups (significance relates to the group in bold).


























































Table 2 Levels of total protein, albumin, low-molecular weight proteins in total and in the four study groups
All patients No cART cART/no TFV cART/TFV p-value TFV/NNRTI TFV/PI p-value
PCR (mg/g) Median (IQR) 82.8 (56.2, 134.6) 73.4 (52.5, 111.8) 84.7 (58.8, 134.2) 82.7 (56.2, 141.9) 0.33 82.9 (60.9, 141.3) 82.6 (50.2, 158.0) 0.88
Log PCR (mg/g) Mean (SD) 4.53 (0.85) 4.37 (0.66) 4.58 (0.93) 4.52 (0.82) >0.05 4.53 (0.82) 4.50 (0.83) 0.82
ACR (mg/g) Median (IQR) 10.3 (5.4, 22.2) 6.8 (4.9, 15.0) 11.5 (5.8, 28.9) 10.0 (5.7, 20.1) 0.10 10.5 (5.7 18.8) 9.6 (5.5, 24.9) 0.26
Log ACR (mg/g) Mean (SD) 2.46 (1.16) 2.19 (1.07) 2.59 (1.26) 4.52 (0.82) >0.05 2.36 (1.08) 2.48 (1.01) 0.24
RBPCR (μg/g) Median (IQR) 66.4 (25.5, 150.4) 61.4 (15.1, 124.6) 60.4 (24.5, 130.4) 75.5 (28.2, 169) 0.24 75.23 (27.2, 138.7) 75.5 (30.6, 241.3) 0.27
Log RBPCR (μg/g) Mean (SD) 3.92 (1.75) 3.64 (1.94) 3.86 (1.69) 4.13 (1.71) >0.05 4.02 (1.66) 4.32 (1.78) 0.58
NGALCR (ng/g) Median (IQR) 17993 (6998, 44823) 19658 (7919, 44728) 20049 (7172, 45319) 14412 (6011, 43756) 0.56 12770 (5491, 47963) 17993 (6998, 42732) 0.44
Log NGALCR (ng/g) Mean (SD) 9.52 (1.99) 9.39 (2.36) 9.67 (1.82) 9.40 (1.99) >0.05 9.40 (1.90) 9.40 (2.17) 0.99
CCR (μg/g) Median (IQR) 2.44 (0.75, 5.39) 2.70 (0.79, 5.23) 2.82 (1.01, 5.51) 1.92 (0.56, 5.10) 0.13 1.92 (0.46, 5.02) 2.04 (0.70, 5.46) 0.44
Log CCR (μg/g) Mean (SD) 0.80 (1.71) 0.64 (1.47) 1.12 (1.82) 0.50 (1.65) 0.02 0.35 (1.66) 0.76 (1.63) 0.29
p value for comparison between study groups.
PCR = protein-creatinine ratio (urine); ACR= albumin-creatinine ratio (urine); RBPCR = retinol-binding protein-creatinine ratio (urine); NGALCR = neutrophil gelatinase-associated lipocalin-creatinine ratio (urine);
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Figure 1 Correlations between RBPCR and CCR (A), NGALCR (B), ACR (C) and PCR (D).
Campbell et al. BMC Nephrology 2012, 13:85 Page 6 of 10
http://www.biomedcentral.com/1471-2369/13/85higher RBPCR measurements (data not shown). Black
ethnicity was the only factor associated with UQ
NGALCR (OR 0.53 [0.32, 0.88], p = 0.01) and higher
current CD4 cell counts the only factor associated with
UQ CCR (OR 0.99 [0.99, 0.99], p = 0.03) in univariate
analysis; multivariate analyses were thus not performed.
Black ethnicity was marginally associated with UQ CCR
(OR 0.59 [0.33, 1.08], p = 0.09) while impaired renal
function and TFV/PI exposure were not related to
higher odds of UQ NGAL or CCR.
Discussion
This study aimed to evaluate urinary concentrations of
three LMWP in relation to total urinary protein and albu-
min in a multiethnic HIV cohort and study potential asso-
ciations of these parameters with the type of cART used.
We observed poor correlations between LMWP and PCR
or ACR, and no significant overall differences in urine
PCR, ACR and LMWP excretion between patients strati-
fied by cART and TFV exposure. RBPCR in 95%
of patients was within the reference range. By contrast,67% of patients had elevated NGALCR measurements.
Black ethnicity was associated with reduced urinary con-
centrations of LMWP, and impaired renal function with
increased urinary RBP concentrations.
Urinary RBP and cystatin C have previously been pro-
posed as biomarkers for monitoring tubular function
in HIV positive patients receiving TFV [25,33]. In a
recent clinical trial, a 50% increase in urinary RBP
excretion was observed in patients who initiated TFV
with an NNRTI, with no change in the abacavir arm
[30]. In a previous cross-sectional study, Hall and col-
leagues reported increased urinary RBP levels in
patients receiving cART including TFV, compared to
patients receiving cART without tenofovir or cART
naive patients [25]. Our study differed from the latter
study in that it included a 3-fold larger cohort, further
stratified patients by TFV/NNRTI and TFV/PI exposure,
and conducted a multivariate analysis of factors asso-
ciated with UQ RBPCR measurements.
The absence of a significant association between raised
RBPCR and TFV exposure in general, or TFV/PI exposure
Table 3 Crude and multivariate-adjusted odds ratios of upper quartile RBPCR
OR (95 % CI) P-value Adjusted OR (95 % CI) P-value
Age (per 10 years increase) 1.65 (1.24, 2.19) <0.001 1.16 (0.82, 1.64) 0.46
Gender (male v female) 1.82 (0.99, 3.31) 0.05
Black ethnicity 0.36 (0.22, 0.61) <0.0001 0.43 (0.24, 0.77) 0.005
Hypertension 1.37 (0.65, 2.89) 0.40
Diabetes 1.15 (0.29, 4.46) 0.84
HBsAg (positive) 0.44 (0.09, 2.00) 0.29
HCV Antibody (positive) 0.99 (0.04, 2.81) 0.98
eGFR
≥90 mL/min/1.73 m2 1 1
75-89 mL/min/1.73 m2 1.91 (1.02, 3.57) 0.04 1.70 (0.88, 3.28) 0.13
<75 mL/min/1.73 m2 5.52 (2.78, 10.9) <0.0001 3.54 (1.61, 7.80) 0.001
Time since HIV diagnosis (per year increase) 1.08 (1.03, 1.14) 0.003 1.02 (0.96, 1.08) 0.4
Nadir CD4 count (per 50 cell increase) 1.03 (0.95, 1.12) 0.47
Current CD4 count (per 50 cell increase) 1.03 (0.98, 1.09) 0.28
Current HIV RNA <50 c/mL 0.86 (0.51, 1.47) 0.61
AIDS (CDC status C) 0.86 (0.04, 1.66) 0.65
cART status
not on cART 1 1
on cART not containing TFV 1.13 (0.53, 2.37) 0.76 1.23 (0.51, 2.99) 0.65
on TFV/NNRTI 1.16 (0.50, 2.68) 0.73 1.06 (0.40, 2.78) 0.91
on TFV/PI 2.50 (1.04, 5.98) 0.04 2.40 (0.84, 6.86) 0.10
RBPCR = retinol-binding protein-creatinine ratio (urine);
Figure 2 Proportion of patients from the four treatment groups at different levels of retinol-binding protein to creatinine ratio.
* P = 0.003 (TFV/PI vs. other groups in patients with RBPCR >343.4 μg/g). Proportion of patients, stratified by cART exposure (no cART: open bars,
cART without TFV: light grey bars, TFV/NNRTI: dark grey bars, TFV/PI: black bars) with retinol-binding protein-creatinine ratio values in the
indicated range.
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had no evidence of clinical renal tubular toxicity, the size
and heterogeneity of the cohort, the assay or the RBPCR
cut-off chosen for our analyses, or unmeasured confound-
ing. Of note, the median RBPCR in a previous study of
patients with TFV-induced Fanconi syndrome was
5593 μg/mmol (49,515 μg/g) [21], which is approximately
100-fold higher than the upper limit of the reference range
of the assay used in our study. As almost all of our
patients had RBPCR measurements within (or slightly
above) the reference range, RBPCR appears to have good
discriminatory value between severe, treatment-limiting
renal tubular disease and normal tubular function or mild,
asymptomatic renal tubular dysfunction.
HIVAN is the predominant cause of end-stage kidney
disease in black patients with HIV infection [3,4,11,12].
In more advanced cases of HIVAN, urinary NGAL con-
centrations are typically elevated, and NGAL has been
put forward as a useful urinary biomarker to aid the
diagnosis of HIVAN [37,38]. Given the strong ethnic
predisposition of HIVAN and that this condition may be
present in patients with preserved renal function and
mild proteinuria [39], it was surprising to find black eth-
nicity to be associated with lower odds of UQ NGALCR.
However, as HIVAN affects only a small proportion of
black patients in the UK [4], it is possible that increased
urinary NGAL levels in those with (subclinical) HIVAN
were masked by generally lower NGAL levels in black
patients without HIVAN.
Our results suggest that RBPCR results may need to
be interpreted in the context of eGFR and ethnicity. The
observed association between ethnicity and tubular bio-
markers is of interest and suggests that tubular handling
of LMWP may be different in patients of different ethnic
backgrounds, or that the prevalence of genetic poly-
morphisms of the organic anion transporters and/or
multi-drug resistant proteins, which have been impli-
cated in the pathogenesis of cART-associated tubular
dysfunction [27,40], may vary by ethnicity. Alternatively,
a higher muscle mass in black patients may have resulted
in higher urinary creatinine concentrations, and thus
somewhat lower RBPCR, NGALCR and CCR values.
In our cohort, NGALCR poorly correlated with either
RBPCR or CCR. Although all these LMWP are generally
proposed as biomarkers of proximal tubular dysfunction,
the lack of correlation may suggest that urinary NGAL
and RBP or cystatin C reflect different types and/or
severity of tubular dysfunction. NGAL is considered
to be a sensitive, early marker of acute kidney injury
(acute tubular necrosis), i.e. of a state of extensive global
injury of proximal tubular cells [35]. By contrast, RBP
and cystatin C may be better markers of specific forms
of proximal tubular dysfunction (such as inherited forms
of Fanconi syndrome) [41] or states where proximaltubular dysfunction relates to mitochondrial toxicity –
and thus a decrease in energy supply - and not to actual
necrosis [21].
In the FRAM study, microalbuminuria was present
in 11% of HIV positive patients, and associated with sev-
eral cardiovascular risk factors including insulin
resistance and hypertension, as well as immunodefi-
ciency [42]. Several studies in the general population
suggest that urine albumin excretion at the level of
microalbuminuria associates with increased risk of car-
diovascular events and death, whereas protein excretion
at the level of macroalbuminuria or clinical proteinuria
(i.e. urine protein >0.5 g/day) predicts both cardiovascu-
lar events and CKD progression [43]. The associations
of elevated albumin and protein excretion with future
risks of developing renal failure, cardiovascular events and
death have also been confirmed in studies in HIV positive
patients [44-47], and thus, urine albumin and protein
excretion should be assessed and taken into account in
cardiovascular and CKD risk reduction strategies.
This study has several limitations. It followed a cross-
sectional design and, thus, longitudinal associations
could not be evaluated. We relied on a single PCR, ACR
and LMWP measurement for our analyses, and we
lacked data on phosphate reabsorption or renal hist-
ology. Despite the overall sample size, the number of
patients receiving TFV/PI was relatively small, and HIV
negative controls were not included. Nonetheless, the
ethnically diverse participants in our study are represen-
tative of the HIV population in the UK, and patients
were only selected by their willingness to participate in
the study and not for the presence or absence of specific
clinical characteristics.Conclusions
This study suggests that urinary LMWP concentrations
in HIV positive patients are unrelated to viral replication
or exposure to cART in general, or exposure to TFV
specifically. RBPCR was within the reported range in
95% of our study subjects, suggesting that RBP may be a
useful marker to distinguish patients with normal tubu-
lar function or mild tubular dysfunction from those with
clinically significant renal tubular disease and Fanconi
syndrome.
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